Biohaven Enrolls 1st Patient in Phase 2/3 Trial of Trigriluzole for Mild to Moderate Alzheimer’s

Biohaven Enrolls 1st Patient in Phase 2/3 Trial of Trigriluzole for Mild to Moderate Alzheimer’s
Biohaven Pharmaceuticals has enrolled the first patient in its Phase 2/3 clinical trial investigating the potential of trigriluzole as a treatment for patients with mild to moderate Alzheimer’s disease. The study, which is currently recruiting, is being conducted in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS) at four clinical sites in the U.S. Trigriluzole, also

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

4 comments

Leave a Comment

Your email address will not be published. Required fields are marked *